Literature DB >> 25098699

Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

Asim K Bag1, Phillip C Cezayirli, Jake J Davenport, Santhosh Gaddikeri, Hassan M Fathallah-Shaykh, Alan Cantor, Xiaosi S Han, Louis B Nabors.   

Abstract

The objective of this study was to evaluate if peritumoral (PT) perfusion parameters obtained from dynamic susceptibility weighted contrast enhanced perfusion MRI can predict overall survival (OS) and progression free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM). Twenty-eight newly diagnosed GBM patients, who were treated with resection followed by concurrent chemoradiation and adjuvant chemotherapy, were included in this study. Evaluated perfusion parameters were pre- and post-treatment PT relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF). Proportional hazard analysis was used to assess the relationship OS, PFS and perfusion parameters. Kaplan-Meier survival estimates and log-rank test were used to characterize and compare the patient groups with high and low perfusion parameter values in terms of OS and PFS. Pretreatment PT rCBV and rCBF were not associated with OS and PFS whereas there was statistically significant association of both posttreatment PT rCBV and rCBF with OS and posttreatment rCBV with PFS (association of PFS and posttreatment rCBF was not statistically significant). Neither the Kaplan-Meier survival estimates nor the log-rank test demonstrated any differences in OS between high and low pretreatment PT rCBV values and rCBF values; however, high and low post-treatment PT rCBV and rCBF values did demonstrate statistically significant difference in OS and PFS. Our study found posttreatment, not pretreatment, PT perfusion parameters can be used to predict OS and PFS in patients with newly diagnosed GBM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098699      PMCID: PMC4206596          DOI: 10.1007/s11060-014-1560-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

Review 1.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Authors:  Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

2.  Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.

Authors:  L S Hu; L C Baxter; K A Smith; B G Feuerstein; J P Karis; J M Eschbacher; S W Coons; P Nakaji; R F Yeh; J Debbins; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-04       Impact factor: 3.825

3.  Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.

Authors:  Andrés Server; Tone E Døli Orheim; Bjørn A Graff; Roger Josefsen; Theresa Kumar; Per H Nakstad
Journal:  Neuroradiology       Date:  2010-07-13       Impact factor: 2.804

4.  Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.

Authors:  H Thomsen; E Steffensen; E-M Larsson
Journal:  Acta Radiol       Date:  2011-11-23       Impact factor: 1.990

5.  Diffusion tensor imaging provides an insight into the microstructure of meningiomas, high-grade gliomas, and peritumoral edema.

Authors:  Frank E De Belder; Antoinette R Oot; Wim Van Hecke; Caroline Venstermans; Tomas Menovsky; Veerle Van Marck; Johan Van Goethem; Luc Van den Hauwe; Marie Vandekerckhove; Paul M Parizel
Journal:  J Comput Assist Tomogr       Date:  2012 Sep-Oct       Impact factor: 1.826

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Magnetic resonance perfusion and permeability imaging in brain tumors.

Authors:  Saulo Lacerda; Meng Law
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

8.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

9.  Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas.

Authors:  K Majchrzak; W Kaspera; J Szymaś; B Bobek-Billewicz; A Hebda; H Majchrzak
Journal:  Neurol Neurochir Pol       Date:  2013 Jul-Aug       Impact factor: 1.621

Review 10.  Posttreatment evaluation of central nervous system gliomas.

Authors:  Mark S Shiroishi; Michael T Booker; Manyoo Agarwal; Nidhi Jain; Ilana Naghi; Alexander Lerner; Meng Law
Journal:  Magn Reson Imaging Clin N Am       Date:  2013-03-16       Impact factor: 2.266

View more
  10 in total

Review 1.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

2.  Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.

Authors:  Luke Macyszyn; Hamed Akbari; Jared M Pisapia; Xiao Da; Mark Attiah; Vadim Pigrish; Yingtao Bi; Sharmistha Pal; Ramana V Davuluri; Laura Roccograndi; Nadia Dahmane; Maria Martinez-Lage; George Biros; Ronald L Wolf; Michel Bilello; Donald M O'Rourke; Christos Davatzikos
Journal:  Neuro Oncol       Date:  2015-07-16       Impact factor: 12.300

3.  Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.

Authors:  I Hwang; S H Choi; C-K Park; T M Kim; S-H Park; J K Won; I H Kim; S-T Lee; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-05       Impact factor: 3.825

4.  Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma.

Authors:  Roberto Sanz-Requena; Antonio J Revert-Ventura; Gracián García-Martí; Fares Salamé-Gamarra; Alexandre Pérez-Girbés; Enrique Mollá-Olmos; Luis Martí-Bonmatí
Journal:  Eur Radiol       Date:  2016-12-20       Impact factor: 5.315

5.  Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.

Authors:  Asim K Bag; Hyunki Kim; Yi Gao; Mark Bolding; Paula P Warren; Hassan M Fathallah-Shaykh; Demet Gurler; James M Markert; John Fiveash; Timothy M Beasley; Ayaz Khawaja; Gregory K Friedman; Philip R Chapman; Louis B Nabors; Xiaosi Han
Journal:  J Neurooncol       Date:  2015-02-25       Impact factor: 4.130

6.  Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.

Authors:  T Jaspan; P S Morgan; M Warmuth-Metz; E Sanchez Aliaga; D Warren; R Calmon; J Grill; D Hargrave; J Garcia; G Zahlmann
Journal:  AJNR Am J Neuroradiol       Date:  2016-04-28       Impact factor: 3.825

Review 7.  Advanced Imaging and Computational Techniques for the Diagnostic and Prognostic Assessment of Malignant Gliomas.

Authors:  Jayapalli Rajiv Bapuraj; Nicholas Wang; Ashok Srinivasan; Arvind Rao
Journal:  Cancer J       Date:  2021 Sep-Oct 01       Impact factor: 3.360

8.  A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma.

Authors:  Michelle M Kim; Yilun Sun; Madhava P Aryal; Hemant A Parmar; Morand Piert; Benjamin Rosen; Charles S Mayo; James M Balter; Matthew Schipper; Nicolette Gabel; Emily M Briceño; Daekeun You; Jason Heth; Wajd Al-Holou; Yoshie Umemura; Denise Leung; Larry Junck; Daniel R Wahl; Theodore S Lawrence; Yue Cao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-29       Impact factor: 8.013

9.  Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival.

Authors:  Prativa Sahoo; Paul Frankel; Julie Ressler; Margarita Gutova; Alexander J Annala; Behnam Badie; Jana Portnow; Karen S Aboody; Massimo D'Apuzzo; Russell C Rockne
Journal:  Stem Cells Int       Date:  2018-03-14       Impact factor: 5.443

Review 10.  Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.

Authors:  Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.